Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
0.2 (1y: -28%)
Market Cap 31.9 M P/E(ttm)
Enterprise Value 3.04 M P/B 0.74
HEB- AMEX (USA)
Hemispherx Biopharma, Inc.
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$0.20
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry		 vs
history
Cash to Debt 110.992
HEB's Cash to Debt is ranked higher than
53% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 46.63 vs. HEB: 110.992 )
HEB' s 10-Year Cash to Debt Range
Min: 2.56   Max: No Debt
Current: 110.99
Equity to Asset 0.757
HEB's Equity to Asset is ranked higher than
75% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.53 vs. HEB: 0.757 )
HEB' s 10-Year Equity to Asset Range
Min: 0.44   Max: 0.95
Current: 0.76
0.44
0.95
Interest Coverage No Debt
HEB's Interest Coverage is ranked higher than
68% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 37.90 vs. HEB: No Debt )
HEB' s 10-Year Interest Coverage Range
Min: No Debt   Max: No Debt
Current: No Debt
F-Score: 3
Z-Score: -4.32
M-Score: -4.81
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry		 vs
history
Operating margin (%) -9549.30
HEB's Operating margin (%) is ranked lower than
96% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -31.50 vs. HEB: -9549.30 )
HEB' s 10-Year Operating margin (%) Range
Min: -12138.5   Max: -886
Current: -9549.3
-12138.5
-886
Net-margin (%) -8147.4
HEB's Net-margin (%) is ranked lower than
95% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -29.90 vs. HEB: -8147.4 )
HEB' s 10-Year Net-margin (%) Range
Min: -12106.3   Max: -1085.3
Current: -8147.4
-12106.3
-1085.3
ROE (%) -38.8
HEB's ROE (%) is ranked lower than
69% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -7.60 vs. HEB: -38.8 )
HEB' s 10-Year ROE (%) Range
Min: -204.5   Max: -21.5
Current: -38.8
-204.5
-21.5
ROA (%) -30.1
HEB's ROA (%) is ranked lower than
67% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -10.10 vs. HEB: -30.1 )
HEB' s 10-Year ROA (%) Range
Min: -122.9   Max: -20.7
Current: -30.1
-122.9
-20.7
EBITDA Growth (%) 6.2
HEB's EBITDA Growth (%) is ranked higher than
81% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. HEB: 6.2 )
HEB' s 10-Year EBITDA Growth (%) Range
Min: -21.5   Max: 12.5
Current: 6.2
-21.5
12.5
ยป HEB's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

HEB Guru Trades in

Q2 2011

HEB Guru Trades in Q2 2011

Jim Simons Sold Out
» More
Q4 2012

HEB Guru Trades in Q4 2012

Jim Simons 330,776 sh (New)
» More
Q1 2013

HEB Guru Trades in Q1 2013

Jim Simons 130,300 sh (-60.61%)
» More
» Details

Insider Trades

Latest Guru Trades with HEB



No Insider Trades Found!

Ratios

vs
industry		 vs
history
P/B 0.74
HEB's P/B is ranked higher than
96% of the 359 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. HEB: 0.74 )
HEB' s 10-Year P/B Range
Min: 0.49   Max: 33.37
Current: 0.74
0.49
33.37
P/S 161.29
HEB's P/S is ranked lower than
90% of the 391 Companies
in the Global Biotechnology industry.

( Industry Median: 7.70 vs. HEB: 161.29 )
HEB' s 10-Year P/S Range
Min: 18   Max: 700
Current: 161.29
18
700
EV-to-EBIT -0.14
HEB's EV-to-EBIT is ranked lower than
92% of the 266 Companies
in the Global Biotechnology industry.

( Industry Median: 21.21 vs. HEB: -0.14 )
HEB' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -0.14

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 1
HEB's Price/Net Cash is ranked higher than
96% of the 189 Companies
in the Global Biotechnology industry.

( Industry Median: 9.50 vs. HEB: 1 )
HEB' s 10-Year Price/Net Cash Range
Min: 1.1   Max: 213
Current: 1
1.1
213
Price/Tangible Book 0.8
HEB's Price/Tangible Book is ranked higher than
96% of the 344 Companies
in the Global Biotechnology industry.

( Industry Median: 4.90 vs. HEB: 0.8 )
HEB' s 10-Year Price/Tangible Book Range
Min: 0.7   Max: 26.6
Current: 0.8
0.7
26.6
Earnings Yield (Greenblatt) 310.90
HEB's Earnings Yield (Greenblatt) is ranked higher than
95% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.70 vs. HEB: 310.90 )
HEB' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.6   Max: 532.3
Current: 310.9
1.6
532.3
Forward Rate of Return (Yacktman) -55.31
HEB's Forward Rate of Return (Yacktman) is ranked lower than
89% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. HEB: -55.31 )
HEB' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -176   Max: -32.9
Current: -55.31
-176
-32.9

Business Description

Hemispherx Biopharma, Inc. is a Delaware Corporation founded in the early 1970s. The company is a specialty pharmaceutical company. It is engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. It has three domestic subsidiaries BioPro Corp., BioAegean Corp., and Core BioTech Corp., all of which are incorporated in Delaware and are dormant. Its foreign subsidiary is Hemispherx Biopharma Europe N.V./S.A. established in Belgium in 1998, which has minimal activity. All significant intercompany balances and transactions have been eliminated in consolidation. Its current strategic focus is derived from four applications of its two core pharmaceutical technology platforms Ampligen and Alferon N Injection. The commercial focus for Ampligen includes application as a treatment for Chronic Fatigue Syndrome ('CFS') and as an influenza vaccine enhancer (adjuvant) for both therapeutic and preventative vaccine development. Alferon N Injection is a Food and Drug Administration ('FDA') approved product with an indication for refractory or recurring genital warts. Alferon LDO (Low Dose Oral) is a formulation currently under development targeting influenza. It owns and operates a 43,000 sq. ft. FDA approved facility in New Brunswick, NJ that produces Alferon and Ampligen. In December 2011, its Board of Directors (the 'Board') reevaluated its facility enhancement project to focus on converting the facility to provide for a high volume, more cost effective manufacturing process for Alferon N Injection, Alferon LDO and Ampligen. In this regard, the Board increased the funding allocated to this project from $4.4 million to $6.5 million. Its primary pharmaceutical product platform consists of its experimental compound, Ampligen, its FDA approved natural interferon product, Alferon N Injection and, its experimental liquid natural interferon for oral administration, Alferon LDO (Low Dose Oral). On March 1, 2012, it had 16 patents worldwide with 85 additional pending patent applications comprising its intellectual property. The company is subject to various federal, state and local laws, regulations and recommendations relating to such matters as safe working conditions, laboratory and manufacturing practices, the experimental use of animals and the use of and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with its research work. Prior to its construction phase, its laboratory and production facility in New Brunswick, New Jersey was approved for the manufacture of Alferon N Injection.
Company Website
SEC Reports
Industry: Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG
Traded in other countries:HXB.Germany
ยป More Articles for HEB

Headlines

Articles On GuruFocus.com
Hemispherx Biopharma Inc Reports Operating Results (10-Q/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-K/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-Q/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-Q/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-Q) Nov 08 2010 
Weekly CEO Sells Highlight: Hemispherx Biopharma Inc, ADESA Inc, Entergy Corp, and Danaher Corp. Aug 15 2010 
Hemispherx Biopharma Inc Reports Operating Results (10-Q) Aug 06 2010 
Hemispherx Biopharma Inc (HEB) CEO William A Carter buys 500,000 Shares Jul 01 2010 
Weekly CFO Buys Highlight: Wireless Telecom Group, ValueVision Media, American River Bankshares, Hem Dec 13 2009 
Hemispherx Biopharma Inc (HEB) CFO Charles Thomas Iii Bernhardt buys 2,000 Shares Dec 08 2009 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial